Remove 2019 Remove Safety Remove Side effects
article thumbnail

Is DTC effective?

World of DTC Marketing

During the first quarter of 2020, the number of telehealth visits increased by 50%, compared with the same period in 2019, with a 154% increase in visits noted in surveillance week 13 in 2020, compared with the same period in 2019. What are the side effects? That belief is out the window.

article thumbnail

Novel anti-epileptic drug demonstrates efficacy

European Pharmaceutical Review

A new approach to potassium-channel openers for epilepsy Critically, XEN1101 combines the effectiveness of potassium-channel openers with the safety of more traditional drugs, stated study lead author and neurologist Dr Jacqueline French. It ran between January 2019 and September 2021.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Almirall/Lilly lebrikizumab offers potential long-term management of atopic dermatitis

pharmaphorum

The week 16 data of lebrikizumab […] points towards a drug with robust efficacy with hardly any safety trade-offs. Minor side effects to long-term maintenance balance. Any clinical study seeks to achieve maximum results efficacy with minimal occurrence of side effects. However, side effects do happen.

article thumbnail

Newron says pivotal treatment-resistant schizophrenia trial is a go

pharmaphorum

Side-effect data from the open-label studies was also encouraging, helping to downplay concerns abut evenamide’s cardiovascular and central nervous system safety that emerged in 2019.

article thumbnail

Meningitis vaccine comes to the forefront with impressive study results

Pharmaceutical Technology

The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. There was no significant difference in side effect profiles of the two vaccines, based on the data. percentage points (96% CI, −0.3 for serogroup W to 20.5

article thumbnail

Developing the EU’s first intestinal microbiota-based biologic

European Pharmaceutical Review

The main objective was to evaluate the efficacy and safety of MBK-01 compared to fidaxomicin, providing significant insights into the potential of MBK-01 as a treatment for primary or recurrent CDI and contributing to the advancement of microbiome-based therapies. 2019; 13(1):16-24. Adverse events were relatively low in both groups (2.22

Safety 111
article thumbnail

Novel oral chemotherapeutic holds potential for stomach cancer patients

European Pharmaceutical Review

There is an urgent need for more effective chemotherapy treatments with less severe toxicity and side effects. Irinotecan – also known by the brand name Campto/Camptosar ® (Pfizer Ltd.) – has proven to be an effective chemotherapy agent against several types of gastrointestinal cancer. 2019; 83(1):169-178.

Patients 104